---
title: "DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune"
description: "Faruqi & Faruqi, LLP is investigating claims on behalf of investors who suffered losses exceeding $75,000 in Altimmune, Inc. between August 10, 2023, and June 25, 2025. Investors are encouraged to con"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251882441.md"
published_at: "2025-08-06T17:39:54.000Z"
---

# DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

> Faruqi & Faruqi, LLP is investigating claims on behalf of investors who suffered losses exceeding $75,000 in Altimmune, Inc. between August 10, 2023, and June 25, 2025. Investors are encouraged to contact partner Josh Wilson regarding their legal rights before the October 6, 2025 deadline to seek lead plaintiff status in a federal securities class action. Following disappointing trial results, Altimmune's stock price plummeted by 53.2% in one day, from $7.71 to $3.61 per share. The firm invites anyone with information about Altimmune's conduct to reach out.

Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options.

### Related Stocks

- [ALT.US - Altimmune](https://longbridge.com/en/quote/ALT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Altimmune 董事 Wayne Pisano 購入普通股 | 韋恩·皮薩諾（Wayne Pisano），Altimmune Inc. 的董事，已購買該公司的普通股。完整的文件可通過提供的鏈接獲取。此消息由公共技術公司生成，僅供參考，不應被視為財務、投資或法律建議。Altimmune Inc. 對於 2 | [Link](https://longbridge.com/en/news/272122963.md) |
| Altimmune 公司董事 Catherine A. Sohn 報告了普通股的收購 | Catherine A. Sohn，Altimmune Inc. 的董事，已報告收購該公司的普通股。完整的文件可通過提供的鏈接獲取。此新聞簡報由公共技術公司生成，僅供信息參考，不應被視為財務、投資或法律建議。Altimmune Inc. 對 | [Link](https://longbridge.com/en/news/271563101.md) |
| Altimmune 公司獲得 FDA 突破性療法認定，用於 Pemvidutide 治療 MASH | Altimmune Inc. 已獲得美國食品藥品監督管理局（FDA）對 pemvidutide 的突破性療法認定，這是一種用於治療代謝功能障礙相關脂肪肝炎（MASH）的雙受體激動劑。該認定是在 IMPACT 2b 期臨牀試驗取得積極結果後獲 | [Link](https://longbridge.com/en/news/271512829.md) |
| Altimmune 董事 Diane Jorkasky 收購普通股 | Diane Jorkasky，Altimmune Inc. 的董事，已購買該公司的普通股。完整的文件可通過提供的鏈接獲取。此消息由公共技術公司生成，僅供信息參考，不應被視為財務或法律建議。Altimmune Inc. 對於 2025 年 1 | [Link](https://longbridge.com/en/news/271030324.md) |
| Altimmune 董事 John Gill 報告了普通股的收購 | Altimmune Inc. 的董事 John Gill 已經收購了該公司的普通股。此事件通過美國證券交易委員會的 EDGAR 系統進行了備案。該信息由 Altimmune Inc. 於 2025 年 12 月 23 日發佈，僅供參考 | [Link](https://longbridge.com/en/news/270655085.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.